SEC Form 4 · accession 0001477932-19-000320
Innovation Pharmaceuticals Inc. · IPIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Leo Ehrlich
Officer — CEO and Chairman · Director · 10% Owner
Period of report
Jan 29, 2019
Accepted (ET)
Jan 31, 2019 · 4:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001355250
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | $0.11 | Jan 29, 2019 | M | 909,090 | D | Dec 30, 2010 | Dec 30, 2020 | Class B Common Stock | 909,090 | 5,090,910 | D |
| Class B Common StockF1 | — | Jan 29, 2019 | A | 909,090 | A | — | — | Class A Common Stock | 909,090 | 909,090 | D |
Explanation of responses
- F1The Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, and has no expiration date.